| Health / Medical Topics |
gp100:209-217(210M) Peptide Vaccine
A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210 designed to improve immunogenicity. Vaccination with gp100:209-217(210M) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing gp100. (NCI Thesaurus)
YOU MAY ALSO LIKE
A synthetic peptide vaccine consisting of the amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with…
A synthetic peptide vaccine consisting of amino acids 17 through 25 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with gp100_17-25…
A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific…
A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum…
Tumor infiltrating lymphocytes (TIL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the…
Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to…
